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Summary and Implications 
 Classical swine fever virus (CSFV) E2 glycoprotein 
was expressed in an alphavirus based replicon expression 
system.  Vaccinated pigs developed CSFV-specific 
antibodies.  This is the first known use of this technology 
against CSFV.    
 
Introduction 
 Classical swine fever virus is the cause of hog cholera.  
CSFV was eradicated from the US in 1978, but remains a 
serious threat to the swine industry.  Alphavirus-derived 
replicon particles (RP) are safe and effective vectors that 
have been developed for use in veterinary vaccines.  
 
Materials and Methods 
 The CSFV E2 gene was codon-optimized and de novo 
synthesized prior to cloning into the replicon DNA plasmid.  
A modified signal sequence was added to the 5’ end of the 
gene, and a histidine tag sequence was added to the 3’ end 
of the gene to facilitate detection in immunoassays.  
Replicon RNA was generated by in vitro transcription using 
T7 RNA polymerase. The CSFV-E2 RP were generated by 
co-electroporation of replicon RNA and helper RNAs into 
Vero cells.  The RP were harvested by affinity 
chromatography and quantified by immunofluorescence. 
Vero cells were infected with CSFV-E2 RP, and cell lysates 
were used for Western blot expression analysis.  Vero cells 
were also infected with CSFV-E2 RP and fixed with 
acetone:methanol for indirect immunofluoresence assay 
(IFA).  Young pigs (n=3) were vaccinated twice with 
CSFV-E2 RP, and serum samples were tested for reactivity 
against fixed, RP-infected Vero cells. 
 
Results and Discussion 
 CSFV E2 expression was confirmed by Western blot 
(Figure 1).  Serum from vaccinated pigs reacted with CSFV-
E2-positive cells by IFA, while control pig serum did not.  
Future work will determine the level of neutralizing 
antibody in vaccinated pigs, and CSFV challenge studies 
will be conducted to evaluate the level of protection 
afforded by RP vaccination. 
 
Figure 1.  Western blot of CSFV E2 expressed in Vero 
cells. 
 
  
 
